LM-302

LM-302 is an antibody-drug conjugate developed by LaNova Medicines Zhejiang and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development. Its target is Claudin 18.2 (the sponsor names CLDN18.2 (Claudin 18.2)). The sponsor states: LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov describes the intervention as: The LM-302 injection is an ADC drug targeting CLDN18.2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07385703 (Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT07385703, plans to enrol 752 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.